检索术语包括:”advanced breast cancer”, “metastatic breast cancer”, “breast cancer metastases”,“cyclin-dependent kinase 4 6 inhibitors”, “CDK 4 6 inhibitors”, “palbociclib”, “ribociclib”, “abemaciclib”, “...
Objective: The aim of this study was to investigate the potential risk of druginduced liver injury (DILI) caused by the CDK4/6 inhibitors (CDK4/6is abemaciclib, ribociclib, and palbociclib by comprehensively analyzing the FDA Adverse Event Reporting System (FAERS) database. ...
[10]Mo H, Renna CE, Moore HCF, et al. Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors. Clin Breast Cancer. 2022 Feb;22(2):143-148. [11]Turner NC, Oliveira M, H...
Specific targets of CDK4/6 inhibitors. CDK4/6 inhibitors specifically bind to CDK4/6, thus inducing G1phase arrest. Although these inhibitors perform the same function in cell cycle progression, their targets are slightly different. Palbociclib inhibits cyclin D1-CDK4, cyclin D2-CDK6, and cyc...
[6]Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review [J]. Ther...
Transcript:Adam M. Brufsky, MD, PhD:So, speaking about really cool science—now that we’ve touched on—the CDK4/6 inhibitors. I’m curious about the more scientifically oriented members of this panel—did you a priori think they were going to work in luminal A disease? Where did that...
Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular transition into S phase and are important for the initiation, growth and survival of many cancer types. Pharmacological inhibitors of CDK4/6 have rapidly become a new standard of care for patients with advanced hormone...
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) were designed to induce cancer cell cycle arrest. Recent studies have suggested that these agents also exert other effects, influencing cancer cell immunogenicity, apoptotic responses and differentiation. Using cell-based and mouse ...
CDK4/6 inhibitors have demonstrated promise in treating patients with estrogen receptor (ER)–positive, HER2-negative breast cancer in both a neoadjuvant and adjuvant setting. CDK4/6 inhibitors have demonstrated promise in treating patients with estrogen receptor (ER)–positiv...
[1] Ma J, Chan JJ, Toh CH, Yap YS. Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer. 2023 Sep 8;9(1):74. [2] Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistan...